factor for vascular disease. New Eng J Med 1991;324:1149-55. 5) Deloughery TG, Evans A, Sadeghi A,et al. Common mutation in methylenetetrahydrofolate reductase: Correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996;94:3074-78. 6) Bostom AG, Selhub J. Homocysteine and arteriosclerosis: Subclinical and clinical disease associations. Circulation 1999;99:2361-63. 7) Boushey CJ, Beresford SAA, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274(13):1049-57. 8) Guttormsen AB, Svarstad E, et al. Elimination of homocysteine in subjects with end-stage renal failure. Irish J Med Sci 1995;164:8. 9) Bostom AG, Lathrop, L. Hyper-homocysteinemia in end- stage renal disease (ESDR): Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.

10)Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. TIPS 1990;11:411-16. 11) Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993;39:1764- 79. 12) Nehler MR, Taylor LM, Porter JM. Homocysteine as a risk factor for atherosclerosis: A Review. Cardiovasc Pathol 1997;6:1-9.

Technical Assistance

In the United States, contact Siemens Medical Solutions Diagnostics Technical Services department.

Tel: 800.372.1782 or 973.927.2828

Fax: 973.927.4101. Outside the United States, contact your National Distributor.

The Quality System of Siemens Medical Solutions Diagnostics is certified to ISO 13485:2003.

Specificity (µmol/L)

 

Amount

 

Compound1

Added2

% Cross

µmol/L

reactivity3

Adenosine

5000

ND

S-adenosyl-L-methionine

500

0.6%

Cystathionine

500

6.1%

L-Cysteine

100000

ND

Glutathione

100000

ND

ND: Not detectable.4

 

 

Linearity (µmol/L)

 

Dilution1 Observed2 Expected3

%O/E4

1

8 in 85

19.2

—

—

 

4 in 8

9.47

9.60

99%

 

2 in 8

4.94

4.80

103%

 

1 in 8

2.11

2.40

88%

2

8 in 8

25.2

—

—

 

4 in 8

13.8

12.6

110%

 

2 in 8

6.15

6.30

98%

 

1 in 8

3.34

3.15

106%

3

8 in 8

31.6

—

—

 

4 in 8

15.7

15.8

99%

 

2 in 8

7.44

7.90

94%

 

1 in 8

3.37

3.95

85%

4

8 in 8

47.5

—

—

 

4 in 8

24.2

23.7

102%

 

2 in 8

11.5

11.9

97%

 

1 in 8

4.91

5.94

83%

Tables and Graphs

Recovery (µmol/L)

 

 

 

 

 

 

 

 

 

 

Solution1 Observed2

Expected3

%O/E4

 

 

 

 

 

 

 

 

 

 

 

Precision (µmol/L)

 

 

 

 

1

—

7.41

—

—

 

 

 

 

 

 

 

A

13.3

13.3

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

Within-Run1

Total2

 

 

B

20.2

19.5

104%

 

 

Mean3

SD4

CV5

SD

CV

 

 

 

C

34.4

32.0

108%

1

3.94

0.29

7.4%

0.41

10.4%

 

 

 

 

 

 

 

 

2

—

9.96

—

—

2

9.88

0.47

4.8%

0.75

7.6%

 

 

 

A

14.7

15.7

94%

3

11.1

0.38

3.4%

0.46

4.1%

 

 

 

B

22.6

22.0

103%

4

25.9

1.06

4.1%

1.31

5.1%

 

 

 

C

36.2

34.5

105%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3

—

13.3

—

—

 

 

 

 

 

 

 

 

 

 

A

16.9

18.9

89%

 

 

 

 

 

 

 

 

 

 

B

26.0

25.1

104%

 

 

 

 

 

 

 

 

 

 

C

32.0

37.6

85%

6

 

 

 

 

 

 

IMMULITE 2000 Homocysteine (PIL2KHO-14, 2007-11-20)